Biomarker-Based Multiple Sclerosis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for multiple sclerosis are inefficient and often take months or years to provide a conclusive diagnosis, due to the disease's variable progression and unpredictable symptoms, making early intervention challenging.
Innovation Solution
Identification of biomarkers in cerebrospinal fluid using advanced proteomic analysis and software programs like Ingenuity Pathway Analysis to diagnose multiple sclerosis and monitor disease progression, allowing for early intervention and appropriate therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (MRI, CSF examination, evoked response testing) are used for multiple sclerosis diagnosis, then diagnostic coverage is comprehensive, but diagnosis time is extended to months or years
Solution Approach 1:
The patent extracts and focuses on specific biomarkers (14-3-3 protein, neurofilament light chain, tau protein) from the complex CSF proteome to create a targeted diagnostic assay. This extraction approach allows rapid detection of disease-specific markers without requiring comprehensive full-proteome analysis, thereby reducing diagnosis time while maintaining accuracy
Solution Approach 2:
The patent performs preliminary identification and validation of specific biomarker signatures that are characteristic of multiple sclerosis. By establishing these predetermined biomarker profiles before clinical application, the diagnostic system can rapidly compare patient samples against known patterns, enabling fast and accurate diagnosis without lengthy investigative processes
2Quantity of substance
If comprehensive proteome analysis is performed on CSF, then multiple proteins can be identified simultaneously, but diagnostic specificity for multiple sclerosis is reduced
Solution Approach 1:
The patent applies local quality by focusing detection efforts on specific biomarkers (14-3-3 protein, neurofilament light chain, tau protein) that have been identified as having high diagnostic value for multiple sclerosis. Rather than treating all proteins equally, the assay optimizes sensitivity and specificity for these particular markers, enabling accurate disease diagnosis without requiring comprehensive proteome coverage
Solution Approach 2:
The patent employs partial action by detecting only the most diagnostically relevant biomarkers rather than performing exhaustive proteome analysis. This selective approach to biomarker detection achieves sufficient diagnostic information with reduced analytical complexity, avoiding the need to identify and analyze all proteins in CSF
3Adaptability or versatility
If variable and unpredictable symptoms of multiple sclerosis are monitored using traditional methods, then all clinical presentations can be captured, but early diagnosis is delayed
Solution Approach 1:
The patent performs preliminary identification and validation of specific biomarker signatures that are characteristic of multiple sclerosis. By establishing these predetermined biomarker profiles before clinical application, the diagnostic system can rapidly compare patient samples against known patterns, enabling fast and accurate diagnosis without lengthy investigative processes
Solution Approach 2:
The patent replaces the mechanical system of progressive clinical evaluation and repeated testing with a direct biochemical detection system. By using laboratory-based biomarker assays on CSF samples, the diagnosis can be obtained rapidly without requiring prolonged clinical observation and multiple follow-up visits
Data Source
Figure 1
AI summary
Biomarkers for the diagnosis of neuropsychiatric diseases are presented herein. In particular embodiments, biomarkers are identified that are useful for diagnosing multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease. Also encompassed is a method for diagnosing a patient with a neuropsychiatric disease, such as multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease, by analyzing biological samples isolated from the patient or the patient as a whole to assess levels of the biomarkers described herein.